Journal Mobile Options
Table of Contents
Vol. 55, No. 6, 2009
Issue release date: December 2009
Section title: Clinical Study
Chemotherapy 2009;55:391–398
(DOI:10.1159/000262452)

Treatment of Recurrent Platinum-Resistant Ovarian Cancer with Pegylated Liposomal Doxorubicin – An Evaluation of the Therapeutic Index with Special Emphasis on Cardiac Toxicity

Steppan I. · Reimer D. · Sevelda U. · Ulmer H. · Marth C. · Zeimet A.G.
aDepartment of Obstetrics and Gynecology and bDepartment of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, Innsbruck, and cDepartment of Obstetrics and Gynecology, Wilhelminenspital, Vienna, Austria

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 2/23/2009
Accepted: 5/21/2009
Published online: 11/30/2009

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 5

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: http://www.karger.com/CHE

Abstract

Background: To study the efficacy of pegylated liposomal doxorubicin (PLD) at a modified dose of 45 mg/m2 every 4 weeks in platinum-resistant ovarian cancer and to evaluate toxicities and effects on quality of life (QoL) of this single-agent regimen. Methods: Treatment response was evaluated by CT scan or CA 125 levels. Toxicity and QoL was recorded according to the common toxicity criteria of the National Cancer Institute and the EORTC QLQ-C30 questionnaire, respectively. Results: Eighty-five patients entered this nationwide observational study (384 cycles administered) and 4 (4.7%) achieved complete and 22 (25.8%) partial remission, giving an objective response rate of 30.5%. Eight patients experienced therapy-limiting side effects prompting discontinuation of treatment. Palmoplantar erythrodysesthesia (PPE) and/or stomatitis were the main reasons for discontinuation. Grade 3–4 PPE and stomatitis occurred in 4.2 and 2.2% of the 384 cycles, respectively. Grade 3–4 cardiotoxicity was absent and overall QoL was not significantly decreased following PLD treatment. Conclusion: Single-agent PLD at a dose of 45 mg/m2 is an efficient treatment in recurrent platinum-resistant ovarian cancer and exhibits an exceptionally favorable therapeutic index.


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 2/23/2009
Accepted: 5/21/2009
Published online: 11/30/2009

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 5

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: http://www.karger.com/CHE


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.